Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in the USA / NCT07490496
Starting soon Phase 3

Phase 3 Bunionectomy Study

NCT07490496 · tracked via the Priya Life Science USA tracker
Sponsor
Cali Pharmaceuticals LLC
Phase
Phase 3
Started
2027-03-01
Last updated
2026-10-21

Condition(s) studied

Postoperative PainBunion

Investigational drug(s) / intervention(s)

CPL-01saline placebo

CPL-01: Administration by the Surgeon during the operation

saline placebo: Administration by the Surgeon during the operation

Study summary

Patients with a bunion will have that repaired and then pain and rescue medicine use will be evaluated.

Eligibility

Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria: * Bunion Exclusion Criteria: * Concomitant conditions

Primary outcome measure(s)

  • Postoperative Pain with activity — 24 hours
    AUC NRS-A wWOCF (Area Under the Curve of the Numeric Rating Scale sore for pain with Activity where 0 is no pain and 10 is worst pain imaginable)

Trial sites (1)

FacilityCityRegionStatus
CenExel Salt Lake City Utah

Other trials for the same condition

Early Weight-Bearing After the Lapiplasty Procedure Active, not recruiting
Patient Satisfaction and Recovery Outcomes Associated With Perioperative ELIXIR MD Use Enrolling by invitation
A Study of TLC590 for Postsurgical Pain Following Bunionectomy Active, not recruiting
Study to Evaluate the Pharmacokinetics and Safety of EXPAREL for Postoperative Analgesia in Subjects Undergoing Cardiac Surgery Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07490496 on ClinicalTrials.gov ↗ ← All trials in the USA